Akero Therapeutics (AKRO) Prices 5.228M Share Common Offering at $36/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Chardan Capital Markets Starts Akero Therapeutics (AKRO) at Buy
July 7, 2020 4:10 AM EDTChardan Capital Markets initiates coverage on Akero Therapeutics (NASDAQ: AKRO) with a Buy rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Akero Therapeutics click here. For more ratings news on Akero Therapeutics click here.
Shares of Akero Therapeutics closed at $34.96 yesterday.
... MoreAkero Therapeutics (AKRO) Announces Proposed 4.75M Common Share Offering
July 6, 2020 7:03 AM EDTAkero Therapeutics, Inc. (NASDAQ: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, announced today that it has commenced an underwritten public offering of 4,750,000 shares of its common... More
